Ads
related to: how to treat secondary hyperparathyroidism- Patient Resources
Learn more about all available
patient resources and information.
- Sign Up For Updates
Fill out the registration form to
be notified on any updates.
- Prescribing Information
See full prescription and usage
information for this treatment.
- Medication Guide
View the medication guide for
this hypoparathyroidism treatment.
- Patient Resources
Search results
Results from the WOW.Com Content Network
It can help treat SHPT by increasing Vitamin D levels and lowering parathyroid hormone or PTH. It is not indicated for people with stage 5 CKD or on dialysis. [citation needed] In the treatment of secondary hyperparathyroidism due to chronic kidney disease on dialysis calcimimetics do not appear to affect the risk of early death. [5]
In patients with secondary hyperparathyroidism, the high PTH levels are an appropriate response to low calcium and treatment must be directed at the underlying cause of this (usually vitamin D deficiency or chronic kidney failure).
Upacicalcet is a drug used to treat secondary hyperparathyroidism (SHPT) - a disease of the parathyroid gland - in dialysis patients. [1] It was approved as Upasita in Japan in June 2021. [2] The drug is given intravenously. The active ingredient is used in the form of its sodium salt.
Another related condition is called secondary hyperparathyroidism (HPT for short), which is common in patients with chronic kidney disease on dialysis. In secondary HPT, the parathyroid glands make too much parathyroid hormone (PTH) because the kidneys have failed, and the calcium and phosphorus are out of balance.
Tertiary hyperparathyroidism is defined by autonomous release of parathyroid hormone while in a hypercalcaemic state. Unlike primary hyperparathyroidism, hypercalcemia in the tertiary form is thought to be the result of resolution of secondary hyperparathyroidism rather than adenoma formation alone. [4] [11] [10]
Etelcalcetide, sold under the brand name Parsabiv, is a calcimimetic medication for the treatment of secondary hyperparathyroidism in people undergoing hemodialysis. It is administered intravenously at the end of each dialysis session. [3] [4] Etelcalcetide functions by binding to and activating the calcium-sensing receptor in the parathyroid ...
Ads
related to: how to treat secondary hyperparathyroidism